RETATRUTIDE — Investigational Triple Receptor Agonist for Metabolic Research

Advanced Metabolic Research | GLP-1, GIP & Glucagon Receptor Agonist | Obesity & Type 2 Diabetes Investigation

Product Overview

Retatrutide is an innovative, first-in-class investigational peptide developed by Eli Lilly, designed to simultaneously activate three key metabolic hormone receptors: GLP-1, GIP, and glucagon.

This triple receptor agonist is being investigated for its potential applications in obesity management, type 2 diabetes, and metabolic disorders.

By targeting multiple pathways involved in appetite regulation, glucose metabolism, energy expenditure, and metabolic homeostasis, retatrutide represents an emerging approach to metabolic pharmacology.

Mechanism of Action

Retatrutide combines three complementary hormonal mechanisms within a single molecule.

• GLP-1 Receptor Activation: Influences appetite regulation, promotes satiety, and supports glucose-dependent insulin secretion.

• GIP Receptor Activation: Participates in glucose-dependent insulin regulation and metabolic signaling.

• Glucagon Receptor Activation: Influences hepatic energy metabolism and may contribute to increased energy expenditure.

• Integrated Metabolic Regulation: Simultaneous activation of these pathways is being investigated for its combined effects on body weight, glycemic control, and energy homeostasis.

Clinical Research & Findings

Retatrutide has demonstrated substantial weight reduction in clinical trials, including advanced Phase III studies.

Reported findings include:

• Up to 24.2% mean body weight reduction after 48 weeks in a Phase II trial involving participants receiving the highest studied dose.

• 28.3% average weight reduction over 80 weeks in the Phase III TRIUMPH-1 study among participants receiving the 12 mg investigational dose.

• Improved glycemic control in studies involving adults with type 2 diabetes.

• Continued investigation of cardiometabolic outcomes, including obesity-related complications and metabolic health.

These results were obtained under controlled clinical trial conditions and should not be interpreted as guaranteed outcomes.

Potential Research Applications

• Obesity Research: Investigation of hormonal pathways involved in body weight regulation.

• Type 2 Diabetes Research: Evaluation of glucose metabolism, insulin response, and glycemic control.

• Energy Homeostasis: Exploration of interactions between appetite, energy intake, and energy expenditure.

• Metabolic Pharmacology: Research into the combined biological effects of GLP-1, GIP, and glucagon receptor activation.

• Cardiometabolic Research: Investigation of obesity-associated metabolic complications.

These represent active areas of clinical investigation rather than approved therapeutic indications.

Clinical Development & Safety

As of November 2026, retatrutide remains an investigational pharmaceutical candidate undergoing advanced clinical development and has not received regulatory approval for general clinical use.

Commonly reported adverse events in clinical trials have included gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Its complete long-term safety profile remains under evaluation.

Although clinical findings are promising, retatrutide's clinical use requires appropriate regulatory authorization and further assessment of its benefits and risks.

Research Use Only

FOR AUTHORIZED SCIENTIFIC AND CLINICAL RESEARCH PURPOSES ONLY.

Intended exclusively for qualified professionals conducting legitimate scientific investigations and appropriately authorized clinical research.

Not approved for general human or veterinary use. Not intended for personal injection, self-administration, or unsupervised therapeutic applications.

Not intended for routine diagnosis, treatment, cure, or prevention of disease outside authorized clinical research.

The designation “Research Use Only” does not constitute authorization to manufacture, distribute, or administer an investigational medicine.

PEPTITAN — PRECISION. SCIENCE. RESEARCH.